Skip to main content
. 2021 Feb 28;10(3):e1258. doi: 10.1002/cti2.1258

Table 1.

Antibody assay comparison

MNT sVNT Genscript ELISA Euroimmun (IgG/IgA; Spike & IgG; N) ELISA Wantai (IgM; RBD) In‐house ELISA (IgM/IgA/IgG; RBD/Spike) Chaotropic‐based dissociation assays Multiplex
Test time 5 days 65 min 120 min (S); 105 min (N) 75 min 48 h 48 h 24 h per detector (antibody isotype or FcR)
Hands‐on user time 7 h 30 min 30 min 30 min ~2.5 h (6 plates) ~3 h (6 plates) ~4 h per detector
Capacity; samples/run 96 samples 96 samples 96 samples 96 samples 10 samples per plate 5 samples per plate 384 samples per detector
Volume of sample per test 28 µL 10 µL 10 µL 10 µL 7.3 µL 7.3 µL 1 µL per detector
Plasma vs serum Either a Either Either Either Either Either Either
Samples run in duplicate or singularly Duplicate in independent assays Singularly (duplicate for samples within the equivocal zone) Singularly (duplicate for samples within the equivocal zone) Singularly (duplicate for samples within the equivocal zone) Singularly Singularly Duplicate in independent assays
Cost per sample (AUD) ~$14 ~$8 ~$8 ~$1.60–$2.20 ~$1.80–$2.40 ~$16
TGA approval 42 Emergency access scheme Emergency access scheme Emergency access scheme
FDA approval 43 Emergency use authorisation Emergency use authorisation (IgG)
Biosafety level BSL 3 BSL 2 BSL 2 BSL 2 BSL 2 BSL 2 BSL 2
Antigen specificity Whole virus RBD S or N RBD S, RBD S, RBD S, S1, S2, RBD, N
Class switching No No Yes Yes Yes No Yes
Antibody avidity No No No No No Yes Yes
Level of expertise High Moderate Moderate Moderate Moderate Moderate High
Standardisation Run specific Yes Yes Yes Yes Yes Bead set specific
Result readout End‐point titre % inhibition Index value Index value End‐point titre Avidity Index MFI
a

Serum preferred.